Vanda Pharmaceuticals Inc. 8-K

What Happened

• Vanda Pharmaceuticals Inc. announced on February 20, 2026 (press release attached as Exhibit 99.1) that the U.S. Food and Drug Administration approved Bysanti™ (milsaperidone).
• The approval covers the acute treatment of manic or mixed episodes associated with bipolar I disorder in adults and the treatment of schizophrenia in adults. The Form 8-K reporting the event was filed on February 23, 2026.

Key Details

• Drug approved: Bysanti™ (generic: milsaperidone).
• Indications: acute treatment of manic or mixed episodes in bipolar I disorder (adults) and treatment of schizophrenia (adults).
• Press release date: February 20, 2026; 8-K filing date: February 23, 2026.
• 8-K signed by Timothy Williams, Senior Vice President, General Counsel and Secretary; press release included as Exhibit 99.1.

Why It Matters

• FDA approval is a major regulatory milestone that authorizes Vanda to market Bysanti in the U.S. for the stated adult indications, potentially adding a new commercial product to the company’s portfolio.
• The filing itself does not disclose launch timing, pricing, or expected revenue; investors should watch for subsequent company announcements and financial disclosures for commercialization plans and potential revenue impact.